416 related articles for article (PubMed ID: 15201746)
1. Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer.
Sved PD; Gomez P; Manoharan M; Kim SS; Soloway MS
J Urol; 2004 Jul; 172(1):98-102. PubMed ID: 15201746
[TBL] [Abstract][Full Text] [Related]
2. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
3. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
4. Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors.
Grober ED; Tsihlias J; Jewett MA; Sweet JM; Evans AJ; Trachtenberg J; Robinette M; Nam RK
Can J Urol; 2004 Feb; 11(1):2157-62. PubMed ID: 15003158
[TBL] [Abstract][Full Text] [Related]
5. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
6. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection.
Gao X; Mohideen N; Flanigan RC; Waters WB; Wojcik EM; Leman CR
J Urol; 2000 Dec; 164(6):1982-6. PubMed ID: 11061896
[TBL] [Abstract][Full Text] [Related]
7. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
8. Prognostic indicators for long term outcome following radical retropubic prostatectomy for prostate cancer involving the seminal vesicles.
Johnson CW; Anastasiadis AG; McKiernan JM; Salomon L; Eaton S; Goluboff ET; Olsson CA; Benson MC
Urol Oncol; 2004; 22(2):107-11. PubMed ID: 15082006
[TBL] [Abstract][Full Text] [Related]
9. Limited value of perineural invasion in radical prostatectomy specimens as a predictor of biochemical recurrence in Japanese men with clinically localized prostate cancer.
Miyake H; Sakai I; Harada K; Eto H; Hara I
Hinyokika Kiyo; 2005 Apr; 51(4):241-6. PubMed ID: 15912782
[TBL] [Abstract][Full Text] [Related]
10. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.
Whittemore DE; Hick EJ; Carter MR; Moul JW; Miranda-Sousa AJ; Sexton WJ
J Urol; 2008 Feb; 179(2):516-22; discussion 522. PubMed ID: 18076949
[TBL] [Abstract][Full Text] [Related]
11. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence.
Corcoran NM; Hong MK; Casey RG; Hurtado-Coll A; Peters J; Harewood L; Goldenberg SL; Hovens CM; Costello AJ; Gleave ME
BJU Int; 2011 Oct; 108(8 Pt 2):E202-10. PubMed ID: 21443656
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone.
Mian BM; Troncoso P; Okihara K; Bhadkamkar V; Johnston D; Reyes AO; Babaian RJ
J Urol; 2002 Apr; 167(4):1675-80. PubMed ID: 11912386
[TBL] [Abstract][Full Text] [Related]
13. Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy.
Amin A; Partin A; Epstein JI
J Urol; 2011 Oct; 186(4):1286-90. PubMed ID: 21862072
[TBL] [Abstract][Full Text] [Related]
14. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
15. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
Thompson RH; Blute ML; Slezak JM; Bergstralh EJ; Leibovich BC
J Urol; 2007 Aug; 178(2):459-63; discussion 463. PubMed ID: 17561132
[TBL] [Abstract][Full Text] [Related]
16. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate.
Gonzalgo ML; Bastian PJ; Mangold LA; Trock BJ; Epstein JI; Walsh PC; Partin AW
Urology; 2006 Jan; 67(1):115-9. PubMed ID: 16413345
[TBL] [Abstract][Full Text] [Related]
17. Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage.
Thomas GV; Schrage MI; Rosenfelt L; Kim JH; Salur G; deKernion JB; Dorey F; Said J; Reiter RE
J Urol; 2000 Dec; 164(6):1987-91. PubMed ID: 11061897
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome.
Pinthus JH; Witkos M; Fleshner NE; Sweet J; Evans A; Jewett MA; Krahn M; Alibhai S; Trachtenberg J
J Urol; 2006 Sep; 176(3):979-84; discussion 984. PubMed ID: 16890675
[TBL] [Abstract][Full Text] [Related]
19. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
[TBL] [Abstract][Full Text] [Related]
20. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens.
Divrik RT; Eroglu A; Sahin A; Zorlu F; Ozen H
Urol Oncol; 2007; 25(5):376-82. PubMed ID: 17826653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
